00013.HK
HUTCHMED (China) Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 22.54
+3.02%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 549.1M | 548.5M | 630.2M | 838.0M | 426.4M |
| Cost of Revenue | 548.0M | 484.6M | 348.9M | 686.4M | 311.1M |
| Gross Profit | 1.1M | 63.9M | 281.3M | 151.6M | 115.3M |
| Operating Expenses | |||||
| R&D Expense | 161.5M | 154.7M | 212.1M | 302.0M | 267.6M |
| SG&A Expense | 107.9M | 103.0M | 112.9M | 133.2M | 136.1M |
| General & Admin Expense | 70.8M | 66.7M | 64.3M | 79.8M | 92.2M |
| Selling & Marketing Expense | 37.1M | 36.3M | 48.6M | 53.4M | 43.9M |
| Other Expenses | (233.5M) | (154.7M) | (3.1M) | (302.0M) | 119.3M |
| Total Operating Expenses | 35.9M | 103.0M | 321.9M | 133.2M | 523.0M |
| Cost and Expenses | 583.9M | 587.7M | 670.8M | 819.6M | 834.1M |
| Operating Income (EBIT) | (34.8M) | (39.2M) | (40.6M) | 18.4M | (407.7M) |
| Non-Operating | |||||
| Interest Income | — | 49.9M | 40.1M | 36.1M | 9.6M |
| Interest Expense | — | 2.9M | 2.9M | 759.0K | 652.0K |
| Net Interest Income | 47.0M | 47.0M | 37.2M | 35.4M | 8.9M |
| Other Non-Op Income/Expense | 54.9M | 560.5M | 39.5M | 87.2M | 47.0M |
| Non-Operating Income (excl Interest) | — | — | (42.4M) | (40.7M) | — |
| EBT (Pre-Tax Income) | 20.1M | 521.3M | 45.4M | 105.6M | (360.7M) |
| Income Tax Expense | 1.7M | 63.6M | 7.2M | 4.5M | (283.0K) |
| Bottom Line | |||||
| Net Income | 17.9M | 456.9M | 37.7M | 100.8M | (360.8M) |
| Earnings from Cont. Ops | 18.4M | 457.7M | 38.2M | 101.1M | (360.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 17.9M | 456.9M | 37.7M | 100.8M | (360.8M) |
| Per Share | |||||
| Basic EPS | HK$0.02 | HK$0.52 | HK$0.04 | HK$0.12 | (HK$0.43) |
| Diluted EPS | HK$0.02 | HK$0.52 | HK$0.04 | HK$0.12 | (HK$0.43) |
| Revenue Per Share | HK$0.63 | HK$0.63 | HK$0.73 | HK$0.99 | HK$0.50 |
| Shares | |||||
| Basic Shares Outstanding | 865.8M | 872.9M | 860.0M | 849.7M | 847.1M |
| Diluted Shares Outstanding | 872.9M | 872.9M | 872.5M | 869.2M | 847.1M |
| Profitability Metrics | |||||
| EBITDA | (20.5M) | (25.9M) | 14.1M | 67.3M | (401.1M) |
| D&A | 14.3M | 13.3M | 12.3M | 8.2M | 8.7M |
| EBIT | (34.8M) | (39.2M) | 1.8M | 59.1M | (409.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026